A new study by UCSF cardiologists and researchers found that high concentrations of cocoa flavanols decrease blood pressure, improve the health of blood vessels and increase the number of circulating angiogenic cells in patients with heart disease. The findings indicate that foods rich in flavanols – such as cocoa products, tea, wine, and various fruits and vegetables – have a cardio-protective benefit for heart disease patients.
Findings are already online and in the July 13, 2010 issue of the Journal of the American College of Cardiology (JACC).
Flavanols are phytonutrient compounds that are found naturally in apples, grapes, tea, cocoa and cherries, which account for the antioxidant effect provided by red wine and green tea. The study found a protective effect from a cocoa drink with 375 mg of flavanols, but according to researchers, a standard or recommended dosage has not yet been defined to achieve optimal health benefit.
The UCSF team has shown for the first time that one of the possible mechanisms of flavanol’s benefit is an increase in the circulation of so-called angiogenic cells in the blood. These cells, also known as early endothelial progenitor cells, are critical for the repair process after vascular injury, and perform function and maintenance roles in the endothelium. Endothelium is the thin layer of cells that line the interior wall of blood vessels.
“Reduced blood vessel function is a hallmark of early development of coronary artery disease,” said cardiologist Yerem Yeghiazarians, MD, senior author, associate professor of medicine, and researcher in the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF. “If we can improve the health and function of damaged blood vessels, heart disease patients will have a better chance of survival.”
In 2005, researchers reported that an increased level of circulating angiogenic cells is associated with a decreased risk of death from cardiovascular causes (New England Journal of Medicine by Werner, N., et al.)
In the current study, the benefit seen from the two-fold increase in circulating angiogenic cells was similar to that achieved by therapy with statins and with lifestyle changes such as exercise and smoking cessation. The benefit demonstrated with cocoa flavanol therapy occurred in addition to the medical regimen already being taken by study participants.
“Our data support the concept that dietary flavanols at the levels provided - in tandem with current medical therapy - are safe, improve cardiovascular function, and increase circulating angiogenic cells, which have previously been shown to correlate positively with long-term cardiovascular outcomes” said Yeghiazarians. “Long-term trials examining the effects of high-flavanol diets on cardiovascular health and function are warranted, but these early findings help us understand how these compounds impact the function of damaged blood vessels.”
The study included 16 coronary artery disease patients aged 64 years (±three years) who received both a high-flavanol cocoa drink (containing 375 mg of flavanols) twice a day over 30 days and later a nutrient-matched low-flavanol cocoa drink (containing 9mg flavanols) twice a day over 30 days. Giving the same study participants both interventions makes this a “crossover” study since participants crossed over from one intervention to the other.
The study was randomized, controlled and “masked” as well, meaning both the doctors and patients were prevented from knowing which variation of the cocoa drink a patient was drinking at a given time until after the study was completed. The patients continued taking all regular medications for their underlying heart disease during the study period, including statin medications for lowering the cholesterol levels to recommended goals.
Researchers calculated the outcome of the cocoa intervention using blood pressure readings, ultrasound to measure dilation of the brachial artery, and cell assays to calculate the number and behavior of circulating angiogenic cells. The tests showed a 47 percent improvement in vasodilation, or widening rather than constriction, of the brachial artery in the high-flavanol time period compared to the low-flavanol period. In addition, circulating angiogenic cells increased 2.2-fold and systolic blood pressure decreased among the high-flavanol versus low-flavanol periods.
“This is exciting data,” Yeghiazarians added. “Our findings demonstrate that a further increase in endothelial function and improvement in blood pressure can be achieved by complementing standard treatment with a flavanol-rich diet. The 80 million Americans impacted by heart disease may be glad to hear this.” Notably, the therapy did not influence fasting glucose levels of study participants. (Fasting glucose is the standard for measuring an individual’s blood sugar level to diagnose conditions such as diabetes and heart disease).
The study was funded by Mars, Inc., and the American Heart Association.
Corresponding author was Christian Heiss, MD, of UCSF’s Division of Cardiology with additional affiliations with the Division of Cardiology, Vascular Medicine and Pulmonology in Dusseldorf, Germany, and the Department of Nutrition at University of California, Davis.
Additional UCSF investigators include Stanton Glantz, PhD; Andrew Boyle, PhD; William Grossman, MD; Shirley Mihardja, PhD; Franca S. Angeli, MD; Nicolas Amabile, MD; Megha Prasad, Sarah Jahn, Melanie Taylor, Wendy May Real, Maelene L. Wong, and Matthew L. Springer, PhD, from UCSF’s Cardiovascular Research Institute and the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research.
Other co-authors include Tienush Rassaf, MD, with the Division of Cardiology, Vascular Medicine and Pulmonology in Dusseldorf, Germany; Javier I. Ottaviani, PhD, and Carl L. Keen, PhD, from the Department of Nutrition at the University of California, Davis; and Hagen Schroeter, PhD, from Mars, Inc.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For further information, visit www.ucsf.edu.